Companies ›Healthcare ›RGEN.O

RGEN.O — NASDAQ Diversified Medical Equipment & Supplies

Rgen.O

$147,06

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

7,5 %

ROE

2,3 %

Net margin

6,6 %

Debt / equity

0,26

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$122,73

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Business description not yet wired for this issuer.

— missing data

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

Generated · model-assisted

Sell-side consensus

BUY23 analysts

19 buy4 hold0 sell

Avg 12m price target182,01

Analyst recommendations

23 analysts · consensus Buy

Buy19

Hold4

Sell0

12-month price target

182,01

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

23 analysts · indicative

Ownership→

T. Rowe Price Investment Management, Inc.

largest disclosed fund holder

Profitability→

2,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning RGEN.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,7 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,4 %−2,7 %−0,9 %

Real Estate−0,7 %+10,9 %−1,3 %

Consumer Staples−0,7 %+2,3 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to RGEN.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR
Congressional trades
CongressLisa McClain — Repligen Corporation - Common2025-10-31 · Republican · MI · Sale · $1,001 - $15,000
CongressLisa McClain — Repligen Corporation - Common2025-10-30 · Republican · MI · Sale · $1,001 - $15,000
CongressLisa McClain — Repligen Corporation - Common2025-10-30 · Republican · MI · Purchase · $1,001 - $15,000
CongressLisa McClain — Repligen Corporation - Common2025-07-22 · Republican · MI · Purchase · $1,001 - $15,000
CongressLisa McClain — Repligen Corporation - Common2025-06-17 · Republican · MI · Sale · $1,001 - $15,000
CongressLisa McClain — Repligen Corporation - Common2025-06-11 · Republican · MI · Purchase · $1,001 - $15,000

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

AI synthesis

GENERATED

## margin_outlook_rationale The company's gross margin is expected to remain stable due to consistent cost management and pricing power in its core markets.

## rd_outlook_rationale Research and development expenditures are projected to stay within historical ranges as the company focuses on incremental improvements to existing product lines.

## capex_outlook_rationale Capital expenditures will likely remain modest as the company maintains a lean infrastructure and prioritizes operational efficiency.

## revenue_outlook_rationale Revenue growth is anticipated to be driven by continued demand for the company's medical equipment and supplies in both domestic and international markets.

## segment_outlook - **Medical Equipment**: Expected to maintain steady growth due to ongoing healthcare infrastructure investments and an aging population. - **Supplies & Distribution**: Projected to benefit from increased demand for consumable medical supplies and efficient logistics operations.

## dilution_sources - No significant dilution sources were identified in the latest 10-K filing or recent investor communications.

## dilution_near_term_probability Low, as the company has not indicated plans for new equity offerings and has sufficient cash reserves to fund operations.

## dilution_expected_timeframe No near-term pressure, as the company's current liquidity position and low debt levels reduce the need for additional capital in the next 12 months.

## concentration_risk Low, as the company operates in a diversified market with multiple revenue streams and geographic presence.

## regulatory_risk Medium, as the healthcare industry is subject to regulatory changes that could impact operations and compliance costs.

## liquidity_risk_rationale The company maintains a strong liquidity position with significant cash reserves and low debt levels, reducing the risk of liquidity constraints.

## credit_risk_rationale Credit risk is low due to the company's strong balance sheet and conservative financial management practices.

— missing data

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$147,06

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$2.11B

Net cashⓘ

$23.8M

Current ratioⓘ

8.4

Debt / equityⓘ

0.3

ROAⓘ

1.7%

ROEⓘ

2.3%

Cash conversionⓘ

240.0%

CapEx / revenueⓘ

-3.5%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures

Subsidiaries1

908 Devices IncMASS.OSubsidiarie95%Source ↗

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs RGEN · multiples and returns

ABT—

Abbott Laboratories

$107,13

187,2B USD

P/E

26,3x

— vs self

Div yield

2,4 %

— vs self

ROE

12,5 %

+10,2 vs self

MDT—

Medtronic PLC

$86,19

110,3B USD

P/E

21,4x

— vs self

Div yield

3,4 %

— vs self

ROE

9,7 %

+7,4 vs self

MDLN—

MEDLINE INC.

$40,47

53,2B USD

P/E

202,6x

— vs self

Div yield

—

— vs self

ROE

—

— vs self

SYK—

Stryker Corp

$341,20

131,8B USD

P/E

38,0x

— vs self

Div yield

—

— vs self

ROE

13,5 %

+11,2 vs self

BDX—

Becton Dickinson And Co

$170,21

48,4B USD

P/E

25,6x

— vs self

Div yield

2,8 %

— vs self

ROE

7,0 %

+4,6 vs self

HSIC—

Henry Schein Inc

$88,21

10,1B USD

P/E

80,5x

— vs self

Div yield

—

— vs self

ROE

3,0 %

+0,6 vs self

BAX—

Baxter International Inc

$28,10

14,5B USD

P/E

—

— vs self

Div yield

2,3 %

— vs self

ROE

-15,4 %

-17,7 vs self

SOLV—

SOLVENTUM CORPORATION

$76,83

13,3B USD

P/E

8,6x

— vs self

Div yield

—

— vs self

ROE

30,8 %

+28,5 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

1,97

Predicted surprise

-0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-06 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	1,97
Revenue	—no estimate	—no estimate	827,6M UNKNOWN ERROR IN UNIVERSE PROCESSING
Operating income	—no estimate	—no estimate	112,5M UNKNOWN ERROR IN UNIVERSE PROCESSING

Full-year consensus mean (period as reported by source) · consensus in UNKNOWN ERROR IN UNIVERSE PROCESSING. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 3 %

Probability

3 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-18 · 1,0× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution23 analysts

Strong buy5

Buy14

Hold4

Sell0

Strong sell0

12-month price target$182,01 · Median $185,62

Low $145,00High $220,00

Operating income · consensus112,5M UNKNOWN ERROR IN UNIVERSE PROCESSING

EPS surprise

−13,1 %

reported vs consensus · miss

Revenue surprise

−10,8 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$145,00

Mean$182,01

Median$185,62

High$220,00

Spot$147,06

+23.8 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin7,5 %Above median

Net Margin6,6 %Above median

ROE2,3 %Above median

Capex / Rev-3,5 %Below median

D/E0,26Above median

Cash Conv2,40Above P75

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-18 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 70 678 sh1 exercises · 13 grants13 insiders

Madaus Martin DDirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
EGLINTON MANNER CARRIEDirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
Pax MargaretDirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
Mhatre RohinDirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
BARTHELEMY NICOLASDirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
DAWES KAREN ADirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
MUIR GLENN PDirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
Konstantinov KonstantinDirector · Stock Option (Right to Buy) → Common StockAcquired 2 239 @ $103,38grant · 2026-05-14
MUIR GLENN PDirector · Stock Option (Right to Buy) → Common StockAcquired 2 434 @ $38,76exercise · 2026-05-07
Loeillot OlivierChief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 25 890 @ $141,91grant · 2026-03-05
Bylund JamesChief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 8 315 @ $141,91grant · 2026-03-05
Garland Jason KCFO · Stock Option (Right to Buy) → Common StockAcquired 8 315 @ $141,91grant · 2026-03-05
KURIYEL RALFSenior VP, R&D · Stock Option (Right to Buy) → Common StockAcquired 5 669 @ $141,91grant · 2026-03-05
Douglass Brian RobbCHIEF PRODUCT OFFICER · Stock Option (Right to Buy) → Common StockAcquired 2 143 @ $163,86grant · 2025-12-31

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

RGEN.O Market data — financials · 2026-05-29
Repligen Corp Market data — analyst estimates · 2026-05-29

Ownership & reference

Top holders

T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,11 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,07 %$1M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,06 %$165M
First Trust Advisors L.P.Investment Managers · as of 2026-03-310,05 %$74M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,04 %$136M
EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,03 %$0M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,03 %$109M
Invesco QQQ TrustFunds · as of 2026-03-310,02 %$151M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,02 %$954M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,02 %$101M
FMR LLCInstitutional Investor · as of 2026-03-310,02 %$340M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$28M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$79M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$52M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,01 %$818M
Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$42M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$77M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$19M
Jennison Associates LLCInvestment Managers · as of 2026-03-310,01 %$14M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$53M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$125M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,01 %$12M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$52M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$12M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$3M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$3M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$4M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$1M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$12M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M

Leadership

Olivier LoeillotPresident, Chief Executive Officer
Sandy D. SmithPresident & CEO

Insider activity

Net selling0 buys · 1 sellsnet -$536K14 insiders · last 365d

Mhatre RohinDirector · Common StockOther 995 · 2026-05-14
Madaus Martin DDirector · Common StockOther 995 · 2026-05-14
Konstantinov KonstantinDirector · Common StockOther 995 · 2026-05-14
EGLINTON MANNER CARRIEDirector · Common StockOther 995 · 2026-05-14
Pax MargaretDirector · Common StockOther 995 · 2026-05-14
MUIR GLENN PDirector · Common StockOther 995 · 2026-05-14
DAWES KAREN ADirector · Common StockOther 995 · 2026-05-14
BARTHELEMY NICOLASDirector · Common StockOther 995 · 2026-05-14
MUIR GLENN PDirector · Common StockOther 2 434 @ $38,76$94K · 2026-05-07
Douglass Brian RobbCHIEF PRODUCT OFFICER · Common StockOther 334 @ $126,43$42K · 2026-05-07
Loeillot OlivierDirector, Chief Executive Officer · Common StockSold 3 832 @ $140,00$536K · 2026-04-21
KURIYEL RALFSenior VP, R&D · Common StockOther 5 284 · 2026-03-05
Garland Jason KCFO · Common StockOther 7 751 · 2026-03-05
Loeillot OlivierChief Executive Officer · Common StockOther 24 134 · 2026-03-05
Bylund JamesChief Operating Officer · Common StockOther 7 751 · 2026-03-05
KURIYEL RALFSenior VP, R&D · Common StockOther 42 @ $125,84$5K · 2026-03-04
Bylund JamesChief Operating Officer · Common StockOther 125 · 2026-03-04
Bylund JamesChief Operating Officer · Common StockOther 62 @ $125,84$8K · 2026-03-04
KURIYEL RALFSenior VP, R&D · Common StockOther 125 · 2026-03-04
Garland Jason KCFO · Common StockOther 715 @ $124,97$89K · 2026-03-02
Loeillot OlivierDirector, Chief Executive Officer · Common StockOther 1 610 @ $124,97$201K · 2026-03-02
KURIYEL RALFSenior VP, R&D · Common StockOther 923 @ $124,97$115K · 2026-03-02
Douglass Brian RobbCHIEF PRODUCT OFFICER · Common StockOther 221 @ $124,97$28K · 2026-03-02
Hunt AnthonyDirector · Common StockOther 9 897 @ $124,97$1,2M · 2026-03-02
Bylund JamesChief Operating Officer · Common StockOther 2 433 @ $124,97$304K · 2026-03-02

Short positioning

5.8Mshares short-3.9% vs prior

7.93days to cover

66.3%short of daily vol

458fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

RGEN.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise-0,00M&A prob3 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 289.1%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 3.2%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -1.6%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 25.4%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -8.4%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 4.2%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 257.1%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 6.8%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.40xDerived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -33.1%Derived (calculated)
Current ratio (FY 2025-12-31): 8.37xDerived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -2.2%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 287.0%Derived (calculated)
Return on assets (FY 2025-12-31): 1.7%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 291.6%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -25.3%Derived (calculated)
Return on equity (FY 2025-12-31): 2.3%Derived (calculated)
Net income (annual): USD 48.89MSEC XBRL filing
Cash & equivalents (annual): USD 566.02MSEC XBRL filing
Operating income (annual): USD 55.17MSEC XBRL filing
Cost of revenue (annual): USD 352.01MSEC XBRL filing
R&D expense (annual): USD 54.18MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES 1SEC XBRL filing
Total assets (annual): USD 2.95BSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-28 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-28EVENTQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-05-15FILING8-K filing →

2026-05-14 00:00 UTCINSIDER19 insider transactions — 2026-05 · $137k gross 9 derivative

2026-05-14INSIDERMhatre Rohin transacted 995 sh — Director

2026-05-14INSIDERMadaus Martin D transacted 995 sh — Director

2026-05-14INSIDERKonstantinov Konstantin transacted 995 sh — Director

2026-05-14INSIDEREGLINTON MANNER CARRIE transacted 995 sh — Director

2026-05-14INSIDERPax Margaret transacted 995 sh — Director

2026-05-14INSIDERMUIR GLENN P transacted 995 sh — Director

2026-05-14INSIDERDAWES KAREN A transacted 995 sh — Director

2026-05-14INSIDERBARTHELEMY NICOLAS transacted 995 sh — Director

2026-05-14INSIDERMadaus Martin D acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-14INSIDERKonstantinov Konstantin acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-14INSIDERBARTHELEMY NICOLAS acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-14INSIDERDAWES KAREN A acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-14INSIDERMUIR GLENN P acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-14INSIDERPax Margaret acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-14INSIDERMhatre Rohin acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-14INSIDEREGLINTON MANNER CARRIE acquired 2.2k sh Stock Option (Right to Buy) — Director

2026-05-07INSIDERMUIR GLENN P transacted 2.4k sh — Director ~$94k

2026-05-07INSIDERDouglass Brian Robb transacted 334 sh — CHIEF PRODUCT OFFICER ~$42k

2026-05-07INSIDERMUIR GLENN P acquired 2.4k sh Stock Option (Right to Buy) — Director

2026-05-06FILING10-Q filing →

2026-05-05FILING8-K filing →

2026-04-21 00:00 UTCINSIDER1 insider transaction — 2026-04 · net sell $536k

2026-04-21INSIDERLoeillot Olivier sold 3.8k sh — Director, Chief Executive Officer ~$536k

2026-04-02FILINGDEF 14A filing →

2026-03-05 00:00 UTCINSIDER18 insider transactions — 2026-03 · net sell $2.0M 4 derivative

2026-03-05INSIDERKURIYEL RALF transacted 5.3k sh — Senior VP, R&D

2026-03-05INSIDERGarland Jason K transacted 7.8k sh — CFO

2026-03-05INSIDERLoeillot Olivier transacted 24.1k sh — Chief Executive Officer

Showing the 40 most recent of 72 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread